Programs

To tackle the human health challenges that face the world today, the FNIH develops collaborations with top experts from government, industry, academia and the not-for-profit sector and provides a neutral environment where we can work productively toward a common goal.

Accelerating Medicines Partnership – Schizophrenia

The Accelerating Medicines Partnership–Schizophrenia is the first neuropsychiatric project of the landmark Accelerating Medicines Partnership program managed by the Foundation for the National Institutes of Health.

Biomarkers Consortium - NiP-Metastatic Prostate Cancer

The NiP- Metastatic Prostate Cancer Project will re-examine the Cou302 database to further optimize the radiographic progression-free survival (rPFS) endpoint to include additional factors that may influence overall survival. The model in development will be a first-in-prostate cancer predictive model to incorporate imaging

Summit Virtual Series: 2020 National Research Summit on Care, Services, and Supports for Persons with Dementia and Their Caregivers

To address the growing need for evidence that improves the type and quality of care and support provided to persons with dementia and their caregivers, the National Institute on Aging (NIA) is hosting the Summit Virtual Meeting Series: 2020 National Research Summit on Care, Services, and Supports for Persons with Dementia and Their Caregivers. The Virtual Summit Series will build on the foundation laid by the 2017 National Research Summit on Care, Services, and Supports for Persons with Dementia and Their Caregivers. This series aims to expand upon what was learned in the previous summit and spark new innovative ideas from those living with dementia, caregivers, researchers, providers, and advocates

2019 NIH GSIG Geroscience Summit

The National Institutes of Health Geroscience Interest Group is hosting a two-day Summit to bring together leading researchers, innovators and public advocates from academia, industry, the non-profit sector and the NIH to discuss geroscience concepts and potential opportunities to advance research on chronic diseases that incorporate principles of geroscience.

Biomarkers Consortium - Neuroscience Symposium

The Neuroscience Steering Committee, led by the FNIH and its co-chairs Dr. Linda Brady, Dr. Hartmuth Kolb, and the emeritus co-chair Dr. Bill Potter, is bringing together experts in the field of neuroscience from industry, NIH, FDA, and academia to present progress to date, next steps, and key obstacles that need to be addressed in order to drive biomarker development in a multitude of neuroscience focus areas. 

2019 Alzheimer's Disease-Related Dementia (ADRD) Summit

The National Institutes of Health (NIH) convened the 3rd Alzheimer's Disease-Related Dementia Summit, that was held on March 14-15, 2019 in Bethesda, Maryland. The 2019 Summit brought together leading researchers, innovators and public advocates from academia, industry, the non-profit sector and NIH to discuss progress made on dementia related research and develop recommendations that will help facilitate new scientific discoveries.

The Moderate Alcohol and Cardiovascular Health Trial (MACH15)

The Moderate Alcohol and Cardiovascular Health Trial (MACH15) was a longitudinal, international clinical trial to determine the effects of moderate alcohol use on cardiovascular disease and diabetes. 

Fogarty International Center's 50th Anniversary

The National Institutes of Health (NIH)’s Fogarty International Center celebrated its 50th anniversary of accomplishments and hosted a Scientific Symposium on May 1st, 2018 at the Natcher Auditorium on NIH’s campus. The program convened a series of panel discussions with NIH leaders, Fogarty grantees, and key stakeholders, to identify key gaps in global health research and strategize future research initiatives.

Accelerating Medicines Partnership - Parkinson's Disease

In 2016, the AMP Executive Committee approved the planning of an AMP effort to confront the challenges presented by Parkinson’s disease (PD). This complements current efforts in the areas of Alzheimer’s disease, type 2 diabetes and the autoimmune disorders of rheumatoid arthritis and systemic lupus erythematosus (lupus). A critical component of this partnership is that all members have agreed to make the AMP Parkinson’s disease (AMP PD) data and analyses publicly available to the broad biomedical community.

The Biomedical Research Community Responds to the Opioids Crisis

As part of a larger national effort to address the opioid crisis, the FNIH is leading the planning effort for a potential public-private scientific partnership that includes the NIH, FDA, the Pharmaceutical Research and Manufacturers of America (PhRMA) and more than 30 biopharmaceutical companies.